These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

196 related items for PubMed ID: 8935803

  • 1. Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin, alpha 1-adrenergic and muscarinic receptors in vivo in rats.
    Bymaster FP, Hemrick-Luecke SK, Perry KW, Fuller RW.
    Psychopharmacology (Berl); 1996 Mar; 124(1-2):87-94. PubMed ID: 8935803
    [Abstract] [Full Text] [Related]

  • 2. The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D1, D2, D3, 5HT2A and muscarinic receptors.
    Zhang W, Bymaster FP.
    Psychopharmacology (Berl); 1999 Jan; 141(3):267-78. PubMed ID: 10027508
    [Abstract] [Full Text] [Related]

  • 3. Effects of atypical antipsychotic drugs on dopamine output in the shell and core of the nucleus accumbens: role of 5-HT(2A) and alpha(1)-adrenoceptor antagonism.
    Marcus MM, Nomikos GG, Svensson TH.
    Eur Neuropsychopharmacol; 2000 Jul; 10(4):245-53. PubMed ID: 10871706
    [Abstract] [Full Text] [Related]

  • 4. Neuroendocrine evidence for antagonism of serotonin and dopamine receptors by olanzapine (LY170053), an antipsychotic drug candidate.
    Fuller RW, Snoddy HD.
    Res Commun Chem Pathol Pharmacol; 1992 Jul; 77(1):87-93. PubMed ID: 1359615
    [Abstract] [Full Text] [Related]

  • 5. S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2)-adrenergic receptors: I. Receptorial, neurochemical, and electrophysiological profile.
    Millan MJ, Gobert A, Newman-Tancredi A, Lejeune F, Cussac D, Rivet JM, Audinot V, Adhumeau A, Brocco M, Nicolas JP, Boutin JA, Despaux N, Peglion JL.
    J Pharmacol Exp Ther; 2000 Jan; 292(1):38-53. PubMed ID: 10604930
    [Abstract] [Full Text] [Related]

  • 6. Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro.
    Bymaster FP, Nelson DL, DeLapp NW, Falcone JF, Eckols K, Truex LL, Foreman MM, Lucaites VL, Calligaro DO.
    Schizophr Res; 1999 May 04; 37(1):107-22. PubMed ID: 10227113
    [Abstract] [Full Text] [Related]

  • 7. Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum.
    Li XM, Perry KW, Wong DT, Bymaster FP.
    Psychopharmacology (Berl); 1998 Mar 04; 136(2):153-61. PubMed ID: 9551772
    [Abstract] [Full Text] [Related]

  • 8. BIMG 80, a novel potential antipsychotic drug: evidence for multireceptor actions and preferential release of dopamine in prefrontal cortex.
    Volonté M, Monferini E, Cerutti M, Fodritto F, Borsini F.
    J Neurochem; 1997 Jul 04; 69(1):182-90. PubMed ID: 9202309
    [Abstract] [Full Text] [Related]

  • 9. Effect of antipsychotic drugs on extracellular serotonin levels in rat medial prefrontal cortex and nucleus accumbens.
    Ichikawa J, Kuroki T, Dai J, Meltzer HY.
    Eur J Pharmacol; 1998 Jun 19; 351(2):163-71. PubMed ID: 9686999
    [Abstract] [Full Text] [Related]

  • 10. Clozapine-induced dopamine levels in the rat striatum and nucleus accumbens are not affected by muscarinic antagonism.
    Gray AM, Connick JH.
    Eur J Pharmacol; 1998 Dec 04; 362(2-3):127-36. PubMed ID: 9874162
    [Abstract] [Full Text] [Related]

  • 11. In vitro and in vivo biochemistry of olanzapine: a novel, atypical antipsychotic drug.
    Bymaster FP, Rasmussen K, Calligaro DO, Nelson DL, DeLapp NW, Wong DT, Moore NA.
    J Clin Psychiatry; 1997 Dec 04; 58 Suppl 10():28-36. PubMed ID: 9265914
    [Abstract] [Full Text] [Related]

  • 12. Extended treatment with typical and atypical antipsychotic drugs differential effects on the densities of dopamine D2-like and GABAA receptors in rat striatum.
    Dean B, Hussain T, Scarr E, Pavey G, Copolov DL.
    Life Sci; 2001 Aug 03; 69(11):1257-68. PubMed ID: 11521750
    [Abstract] [Full Text] [Related]

  • 13. Cholinergic modulation of basal and amphetamine-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens.
    Ichikawa J, Chung YC, Li Z, Dai J, Meltzer HY.
    Brain Res; 2002 Dec 20; 958(1):176-84. PubMed ID: 12468043
    [Abstract] [Full Text] [Related]

  • 14. Effect of olanzapine on functional responses from sensitized D1-dopamine receptors in rats with neonatal dopamine loss.
    Moy SS, Knapp DJ, Breese GR.
    Neuropsychopharmacology; 2001 Aug 20; 25(2):224-33. PubMed ID: 11425506
    [Abstract] [Full Text] [Related]

  • 15. Ritanserin potentiates the stimulatory effects of raclopride on neuronal activity and dopamine release selectivity in the mesolimbic dopaminergic system.
    Andersson JL, Nomikos GG, Marcus M, Hertel P, Mathé JM, Svensson TH.
    Naunyn Schmiedebergs Arch Pharmacol; 1995 Oct 20; 352(4):374-85. PubMed ID: 8532065
    [Abstract] [Full Text] [Related]

  • 16. Olanzapine: a basic science update.
    Bymaster F, Perry KW, Nelson DL, Wong DT, Rasmussen K, Moore NA, Calligaro DO.
    Br J Psychiatry Suppl; 1999 Oct 20; (37):36-40. PubMed ID: 10211140
    [Abstract] [Full Text] [Related]

  • 17. Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine and serotonin receptor subtype selective antagonists in mice.
    Gleason SD, Shannon HE.
    Psychopharmacology (Berl); 1997 Jan 20; 129(1):79-84. PubMed ID: 9122367
    [Abstract] [Full Text] [Related]

  • 18. Muscarinic antagonists in substantia nigra influence the decarboxylation of L-dopa in striatum.
    Izurieta-Sánchez P, Sarre S, Ebinger G, Michotte Y.
    Eur J Pharmacol; 2000 Jul 07; 399(2-3):151-60. PubMed ID: 10884514
    [Abstract] [Full Text] [Related]

  • 19. Dopamine D(3) receptors modulate evoked dopamine release from slices of rat nucleus accumbens via muscarinic receptors, but not from the striatum.
    Yamada S, Harano M, Annoh N, Tanaka M.
    J Pharmacol Exp Ther; 1999 Dec 07; 291(3):994-8. PubMed ID: 10565816
    [Abstract] [Full Text] [Related]

  • 20. Radioreceptor binding profile of the atypical antipsychotic olanzapine.
    Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, Seeman P, Wong DT.
    Neuropsychopharmacology; 1996 Feb 07; 14(2):87-96. PubMed ID: 8822531
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.